Surrozen(NASDAQ) SRZN

Surrozen, Inc. creates medicines that help bodies repair damaged tissues. These treatments focus on eye diseases to help patients save vision. The technology mimics natural proteins that fix the eye's structure.

Medicines for the Eyes

• SZN-8141: Antibody therapy for eye diseases caused by diabetes and aging; targets the repair of blood vessels in the retina.
• SZN-8143: Multi-action treatment candidate for swelling in the retina and middle layer of the eye.
• SZN-413: Protein-based medicine designed to restore blood vessel function in the eye; currently in early clinical testing.
• SZN-113: Research-stage program focusing on corneal diseases and vision loss caused by the breakdown of eye tissue.

Strategic Moves and Milestones

• Partnered with Boehringer Ingelheim in Oct. 2022 to develop and commercialize specific eye treatments.
• Received a $10.0 million milestone payment in Sept. 2024 for advancing the development of a key drug candidate.
• Secured $175.0 million in committed funding through a private stock sale in March 2025.
• Triggered a $5.0 million payment in June 2026 by starting the first phase of human clinical trials for SZN-413.

Restoring Function to Tissues

The company uses proprietary technology to activate the Wnt pathway, which is a biological system that manages tissue repair. This approach targets specific tissues to restore normal function instead of only treating disease symptoms.

Key Financial Results

• Collaboration revenue was $10.0 million for the six-month period ended June 30, 2026, up from zero in 2025.
• Research and development expenses were $17.8 million for the six-month period ended June 30, 2026, up 41% year over year.
• General and administrative expenses were $13.0 million for the six months ended June 30, 2026, up 64% year over year.
• Net loss reached $77.3 million for the six-month period ended June 30, 2026, compared to a net income of $12.8 million in the prior-year period.
• Market cap reached $302.7 million in the second quarter of 2026, up 296.4% year over year.

Path to Patient Care

Surrozen has transitioned from a broad research platform to a focused biotechnology company advancing multiple candidates into clinical testing. Its evolution is supported by strategic pharmaceutical partnerships and targeted funding for eye disease research.